Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)

Authors Govan VA

Published 8 February 2008 Volume 2008:4(1) Pages 65—70

DOI https://doi.org/10.2147/TCRM.S856

Vandana A Govan

Division of Medical Virology, Department of Clinical Laboratory Sciences and Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa

Abstract: Human papillomaviruses (HPVs) are one of the most common sexually transmitted infections and remains a public health problem worldwide. There is strong evidence that HPV causes cervical, vulva and vaginal cancers, genital warts and recurrent respiratory papillomatosis. The current treatments for HPV-induced infections are ineffective and recurrence is commonplace. Therefore, to reduce the burden of HPV-induced infections, several studies have investigated the efficacy of different prophylactic vaccines in clinical human trials directed against HPV types 6, 11, 16, or 18. Notably, these HPV types contribute to a significant proportion of disease worldwide. This review will focus on the published results of Merck & Co’s prophylactic quadrivalent recombinant vaccine targeting HPV types 6, 11, 16, and 18 (referred to as Gardasil®). Data from the Phase III trial demonstrated that Gardasil was 100% effi cacious in preventing precancerous lesions of the cervix, vulva, and vagina and effective against genital warts. Due to the success of these human clinical trials, the FDA approved the registration of Gardasil on the 8 June 2006. In addition, since Gardasil has been efficacious for 5 years post vaccination, the longest evaluation of an HPV vaccine, it is expected to reduce the incidence of these type specific HPV-induced diseases in the future.

Keywords: Gardasil, HPV, prophylactic vaccine, cervical disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

Shubham Pant, Meena P Chilukuri, Bhuvaneswari Ramaswamy

Therapeutics and Clinical Risk Management 2008, 4:419-424

Published Date: 11 April 2008

Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy

Mischel G Neill, Rohan Shahani, Alexandre R Zlotta

Therapeutics and Clinical Risk Management 2008, 4:11-18

Published Date: 8 February 2008

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Jason W Bennett, James S Lewis II, Michael W Ellis

Therapeutics and Clinical Risk Management 2008, 4:31-40

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Mark A Ware, Paul Daeninck, Vincent Maida

Therapeutics and Clinical Risk Management 2008, 4:99-107

Published Date: 8 February 2008

Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial

Hong-nü Chu, Mei-juan Shen

Therapeutics and Clinical Risk Management 2008, 4:287-290

Published Date: 8 February 2008

Cannabinoids in the management of difficult to treat pain

Ethan B Russo

Therapeutics and Clinical Risk Management 2008, 4:245-259

Published Date: 8 February 2008